Key Points Compass Pathways completed its New Drug Application submission for COMP360 psilocybin in treatment-resistant depression. The application draws on two Phase 3 trials and…
November 09, 2026
Key Points BrainsWay and Mindful Health Solutions are collaborating to expand access to noninvasive mental health treatments. The initiative includes BrainsWay Deep TMS and its…
November 02, 2026
Compass Pathways and DBSA Survey Highlights Burden of Treatment-Resistant Depression
Key Points A national survey included 261 people living with treatment-resistant depression and 73 caregivers. Some 95% of surveyed patients described themselves as functioning but…
October 26, 2026
BrainsWay Expands U.S. Insurance Coverage for Deep TMS in OCD to More Than 118 Million Lives
BrainsWay Ltd. (NASDAQ: BWAY), a developer of noninvasive brain stimulation treatments for mental health disorders, announced on October 26, 2026 that more U.S. medical policies…
October 20, 2026
Vistagen Brings In GATC Health’s Predictive AI as It Plans the Next Fasedienol Phase 3
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company developing intranasal product candidates called pherines, announced on October 20, 2026 a collaboration with GATC Health, a…
Key Points NRx Pharmaceuticals completed three commercial-scale validation lots of its preservative-free ketamine. Two-year room-temperature testing showed no deterioration in purity, potency or sterility, according…
October 15, 2026
NRx Receives FDA Labeling Review Letter Ahead of November Goal Date for Preservative-Free Ketamine
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a biopharmaceutical company focused on neuroplastic therapies for depression, PTSD and related conditions, announced on October 15, 2026 that it…
October 15, 2026
Vanda Pauses VQW-765 Program After Phase III Social Anxiety Study Misses Primary Endpoint
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a commercial-stage company with approved treatments in psychiatry, sleep and neurology, provided an update on October 14, 2026 on VQW-765,…
October 14, 2026
Compass Pathways Teams Up With Mental Health Groups to Raise Awareness of Treatment-Resistant Depression
Key Points Compass Pathways announced the first-ever U.S. Treatment-Resistant Depression Awareness Day, with support from NAMI, Mental Health America and the Depression and Bipolar Support…
October 13, 2026
BrainsWay Expands Insurance Coverage for Accelerated Deep TMS to Over 70 Million U.S. Lives
Key Points BrainsWay says favorable U.S. insurance policies for its SWIFT Accelerated Deep TMS protocol now cover more than 70 million lives. The expansion creates…
World Mental Health Day 2026: Why Lived Experience Now Moves Markets This Saturday, October 10, marks World Mental Health Day. The World Federation for Mental…
October 08, 2026
Rett Syndrome Awareness Month: Acadia Extends Drug Protection as Taysha Gene Therapy Nears Pivotal Data
Acadia has the first approved Rett syndrome treatment and a path to five more years of U.S. exclusivity. Taysha has finished dosing a pivotal trial…